Well, this study is not exactly Paul Revere territory; nevertheless, the blog title seemed better than “Eat Shit for C diff.”
BP Vaughn et al. Clin Gastroenterol Hepatol 2023; 21: 1330-1337. Effectiveness and Safety of Colonic and Capsule Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection
Methods: Clinical outcomes and adverse events after FMT performed for rCDI at 6 sites (n=269) were captured in a prospective registry. FMT was performed using either freeze-dried/encapsulated or frozen-thawed/liquid.
The authors note that the cohort with a mix of academic and private practices reflects real-world use of FMT. Since the study products were free of charge, providers and patients selected treatment based on their preference (65% selected oral capsule).
Key findings:
- At 1 month, rCDI cure rate was 91% for FMT-colonoscopy and 84% for FMT-capsule (no significant difference, p=0.12)
- At 2 months, rCDI were 83% and 81% for FMT-colonoscopy and FMT-capsule respectively
- Use of non-CDI antibiotics increased failure rates: 28% at 2 months compared to 10% who did not receive antibiotics
- One serious adverse event was related to colonoscopy (aspiration pneumonia), otherwise no new safety signals were identified
My take: This study indicates similar effectiveness of FMT-capsule to FMT-colonoscopy. FMT-capsule is easier and avoids risks associated with colonoscopy. But, it does require patients to eat (encapsulated) feces
Related blog posts:
- How Effective and Safe is Fecal Microbiota Transplantation in Immunocompromised Pediatric Patients with Clostridioides difficile?
- Microbiome Therapy (SER-109) for Recurrent Clostrioides Difficile
- FMT in the “Real World”
- Two Studies: 1. COVID-19 Transmissibility 2.Fecal Microbiota Transplantation in 372 Children
- Large Study Shows FMT Efficacy/Safety in Children | gutsandgrowth
gutsandgrowth 